Daniel Choi, MD
Cornea and External Diseases Specialist · Honolulu, HINPI 1760820633
Payments from drug & device makers
Across 365 payments — averaging $139.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Rxsight Inc$30K
- Glaukos Corporation$6K
- Alcon$3K
- Sight Sciences, Inc.$2K
- Stryker$1K
- Kala Pharmaceuticals, Inc.$1K
- plus $7K from 29 others
What the payments were for
- Consulting fees$5,38826%
- Travel & lodging$1,3496%
- Food & beverage$13,98467%
- Education$580%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- KXL System$2,208
- mild Device Kit$1,272
- OMNI(R) SURGICAL SYSTEM (US)$1,211
- EYSUVIS$1,200
- Rocklatan$1,196
- Rhopressa$967
- OPTABLATE$765
- Photrexa$531
- Clareon$373
- Photrexa Viscous and Photrexa$346
- iDoseTR$346
- iStent inject W$276
- ARGOS$271
- XIIDRA$271
- Hydrus Microstent$186
- iStent Infinite$186
- COOLIEF* COOLED RADIOFREQUENCY$149
- LenSx$147
- ReSTOR$141
- TYRVAYA$132
How this compares
Too few cornea and external diseases specialist providers in Hawaiito place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 110 | $160,325 |
| XiidraLifitegrast | 40 | $70,232 |
| CequaCyclosporine | 24 | $31,100 |
| RhopressaNetarsudil Mesylate | 23 | $28,211 |
| RocklatanNetarsudil Mesylat/Latanoprost | 30 | $27,279 |
| Latanoprost | 825 | $21,691 |
| MieboPerfluorohexyloctane/Pf | 12 | $19,562 |
| LumiganBimatoprost | 21 | $17,958 |
| CombiganBrimonidine Tartrate/Timolol | 31 | $14,300 |
| VyzultaLatanoprostene Bunod | 19 | $13,495 |
| Prednisolone Acetate | 233 | $8,636 |
| Loteprednol Etabonate | 27 | $5,897 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 94 | $5,459 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 220 | $4,759 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 24 | $4,362 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $706 | $192,583162 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta | $192 | $103,28971 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $1,050 | $55,48953 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $553 | $31,10024 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $228 | $5,89727 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few cornea and external diseases specialist providers in Hawaiion file to place this against a meaningful peer group, so we don't.
Other cornea and external diseases specialist in Honolulu
- Sila BalHonolulu$23K
- Kristin HirabayashiHonolulu$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.